Key facts for DRG 018
- FY2027 relative weight
- 45.1464
- Higher than 100% of all MS-DRGs
- Change vs FY2026
- +4.6%
- FY2026 weight 43.1828
- Geometric mean LOS
- 11.4 days
- Arithmetic mean 13.3 days
- MDC
- Pre-MDC
- Pre-MDC (transplants, tracheostomy, ECMO)
- Severity level
- single severity level
- National unadjusted operating payment
- $309,162.55
- Weight × $6,848.00 FY2027 standardized amount; capital adds $24,376.80
- Transfer policy
- Not a transfer DRG
TL;DR
MS-DRG 018 is a medical group in the Pre-MDC set (transplants, tracheostomy and ECMO), with no CC/MCC severity split. CMS assigns it a FY2027 relative weight of 45.1464 with a geometric mean length of stay of 11.4 days and an arithmetic mean of 13.3. Its weight moved up 4.6% from FY2026 (43.1828). That weight is in the top 1% of all MS-DRGs. The v44 Definitions Manual assigns it through 8 t-cell immunotherapy (operating room procedures) codes and 34 t-cell immunotherapy (non-operating room procedures) codes.
What changed from FY2026 to FY2027
CMS recalibrates every MS-DRG weight annually from the prior year's MedPAR claims. For DRG 018 the FY2027 relative weight is 45.1464 against 43.1828 in FY2026, a rise of 4.55%, which exceeds the 2% threshold worth re-checking in contract models.
| Metric | FY2026 | FY2027 | Change |
|---|---|---|---|
| Relative weight | 43.1828 | 45.1464 | +1.9636 |
| Geometric mean LOS (days) | 12.4 | 11.4 | -1.0 |
| Arithmetic mean LOS (days) | 14.7 | 13.3 | -1.4 |
CC and MCC family
DRG 018 stands alone: CMS does not split this base group by CC or MCC severity, so complication documentation does not move the assignment, although it still affects quality and risk-adjustment reporting.
National unadjusted payment for DRG 018
Multiplying the FY2027 relative weight (45.1464) by the national rates in IPPS Tables 1A and 1D, as corrected by notice CMS-1849-CN3, gives the base amounts below. This group has no CC/MCC sibling, so the amount does not change with secondary-diagnosis capture.
| Component | National rate | DRG 018 |
|---|---|---|
| Operating (labor and nonlabor share) | $4,519.68 + $2,328.32 = $6,848.00 | $309,162.55 |
| Capital (federal rate) | $539.95 | $24,376.80 |
| Operating plus capital | $333,539.35 |
These are national, unadjusted figures, not what a given hospital is paid. The labor share is multiplied by the hospital's wage index (Table 1A applies when the wage index is above 1.0 and Table 1B otherwise), and teaching (IME), disproportionate share (DSH), outlier, transfer and new-technology add-on rules then change the amount for each stay. Use the figures to compare groups and to size a documentation finding, not to forecast a remittance; the DRG payment calculator applies a hospital's own wage index and teaching and DSH factors to DRG 018.
New for FY2027: codes that group to DRG 018
IPPS Tables 6A and 6B assign 2 new ICD-10-PCS codes to DRG 018 from October 1, 2026. Encoders and edit tables that still run the v43 code set reject these codes or group them elsewhere, so check them first when a FY2027 discharge in this DRG fails an edit. The FY2027 ICD-10 code-change report lists every addition and deletion with its CC level and MS-DRGs.
| ICD-10-PCS | Description | O.R. | Effective |
|---|---|---|---|
| XW0331B | Introduction of Anitocabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 11 | No | 2026-04-01 |
| XW0431B | Introduction of Anitocabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 11 | No | 2026-04-01 |
Grouper logic (v44 Definitions Manual)
T-cell Immunotherapy (Operating Room Procedures): 8 ICD-10-PCS codes in this DRG's assignment logic.
| ICD-10-PCS code | Description |
|---|---|
| XHR0XGA | Replacement of Head and Neck Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10 |
| XHR1XGA | Replacement of Chest Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10 |
| XHR2XGA | Replacement of Abdomen Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10 |
| XHR3XGA | Replacement of Back Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10 |
| XHR4XGA | Replacement of Right Upper Extremity Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10 |
| XHR5XGA | Replacement of Left Upper Extremity Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10 |
| XHR6XGA | Replacement of Right Lower Extremity Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10 |
| XHR7XGA | Replacement of Left Lower Extremity Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10 |
T-cell Immunotherapy (Non-Operating Room Procedures): 34 ICD-10-PCS codes in this DRG's assignment logic; the first 12 are shown.
| ICD-10-PCS code | Description |
|---|---|
| XW0331B | Introduction of Anitocabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 11 |
| XW03368 | Introduction of Afamitresgene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8 |
| XW03378 | Introduction of Tabelecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8 |
| XW0338A | Introduction of Obecabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 10 |
| XW033A7 | Introduction of Ciltacabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
| XW033BA | Introduction of Orca-T Allogeneic T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 10 |
| XW033C7 | Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
| XW033FA | Introduction of Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy into Peripheral Vein, Percutaneous Approach, New Technology Group 10 |
| XW033FB | Introduction of Valoctocogene Roxaparvovec-rvox into Peripheral Vein, Percutaneous Approach, New Technology Group 11 |
| XW033G7 | Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
| XW033H7 | Introduction of Axicabtagene Ciloleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
| XW033J7 | Introduction of Tisagenlecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7 |
Documentation and denial exposure
As a medical DRG, assignment depends on the principal diagnosis sequenced from the attending's documentation; a secondary condition sequenced first, or a symptom code in place of the confirmed diagnosis, changes the MDC or the DRG. Because this family has no severity split, review risk concentrates on medical-necessity of the admission itself and on the two-midnight benchmark. Typical inpatient denial codes for this group: CARC 16 (claim lacks information needed to group the stay), CARC 50 (the admission or procedure is judged not medically necessary), CARC 97 (a service is bundled into the DRG payment).
For teams evaluating QuickIntell software
Evaluate a documentation and coding workflow for DRG 018
Explore QuickCode for qualified coder review and documentation clarification, or QuickScribe for clinician-reviewed visit documentation. Confirm inpatient scope, the supported grouper version and reviewer responsibilities during evaluation. This public reference is not a production grouper and does not determine a claim's reimbursement.
Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.
Frequently asked questions — DRG 018
What is MS-DRG 018?
MS-DRG 018 is "Chimeric Antigen Receptor (CAR) T-Cell and Other Immunotherapies", a medical Medicare Severity Diagnosis-Related Group in the Pre-MDC set (transplants, tracheostomy and ECMO). Medicare pays inpatient stays grouped here at the hospital's base rate multiplied by the DRG relative weight.
What is the FY2027 relative weight for DRG 018?
The FY2027 relative weight is 45.1464 (IPPS final rule Table 5, effective October 1, 2026). In FY2026 it was 43.1828, a change of +4.6%.
What is the Medicare base payment for MS-DRG 018?
$309,162.55 for operating costs plus $24,376.80 for capital, $333,539.35 together, at the FY2027 national rates: weight 45.1464 times the $6,848.00 operating standardized amount and the $539.95 capital rate (IPPS Tables 1A and 1D as corrected by CMS-1849-CN3). The hospital's wage index, IME, DSH, outlier and transfer adjustments change what a given stay is paid.
What is the average length of stay for DRG 018?
CMS reports a geometric mean length of stay of 11.4 days and an arithmetic mean of 13.3 days for FY2027. The geometric mean is used for transfer-payment calculations.
What documentation supports the severity level of DRG 018?
DRG 018 has no CC or MCC sibling, so secondary-diagnosis capture does not change the group or its 45.1464 weight. Review effort belongs instead on the principal diagnosis sequencing and the 8 procedure codes that place the stay in this group, and on medical necessity of the inpatient admission itself under the two-midnight benchmark against a 11.4-day geometric mean stay, which is where denials for single-severity groups concentrate.
Which codes group to DRG 018?
The v44 Definitions Manual lists 8 t-cell immunotherapy (operating room procedures) codes and 34 t-cell immunotherapy (non-operating room procedures) codes for this group. Examples from the t-cell immunotherapy (operating room procedures) list, XHR6XGA (Replacement of Right Lower Extremity Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10); XHR7XGA (Replacement of Left Lower Extremity Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10); and from the t-cell immunotherapy (non-operating room procedures) list, XW033H7 (Introduction of Axicabtagene Ciloleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7); XW033J7 (Introduction of Tisagenlecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7).
Is DRG 018 a post-acute transfer DRG?
No. DRG 018 is not on the FY2027 post-acute care transfer list, so the transfer per-diem policy does not apply to it.
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- IPPS FY2027 Table 5 as corrected by correction notice CMS-1849-CN3Version v44 FY2027 (final rule + CN3) · effective 2026-10-01 · file CMS-1849-CN Table 5.txtSHA-256 2cc4e0b083e62e40…
- IPPS FY2026 Final Rule Table 5 (CMS-1833-F)Version v43 FY2026 · effective 2025-10-01 · file CMS-1833-F Table 5.txtSHA-256 bf8c390d14b3cd3e…
- ICD-10 MS-DRG Definitions Manual v44 (text)Version v44 · effective 2026-10-01 · file fy2027-fr-icd10-ms-drg-definitions-manual-files-v44.zipSHA-256 ae4f6c11727fe91f…
Disclaimer
This page is an operational reference compiled from the CMS IPPS FY2027 final rule (Table 5) and the v44 ICD-10 MS-DRG Definitions Manual. Relative weights are national factors; actual payment depends on each hospital's wage-adjusted base rate, add-ons, outliers and transfer adjustments. Nothing here is legal, clinical or billing advice; verify grouping against your encoder and the published CMS files.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.